Fuso Pharmaceutical Industries | Dialysis Drug Development Company of
Pharma Tech Outlook

Pharma Tech Outlook

Fuso Pharmaceutical Industries
A Legacy of Trust in Dialysis Care

Fuso Pharmaceutical Industries: A Legacy of Trust in Dialysis Care

Mikio Toda, Fuso Pharmaceutical Industries | Pharma Tech Outlook | Dialysis Drug Development Company of the Year in AsiaMikio Toda, President and Representative Director
For Fuso Pharmaceutical Industries, dialysis medicines represent a life-support responsibility. The company stands at the center of Japan’s dialysis ecosystem, advancing renal care through clinically validated hemodialysis solutions that balance centralized delivery with individualized patient management across diverse clinical settings. Its fully integrated supply infrastructure and extensive product lineup ensure that healthcare providers receive uninterrupted access to dialysis solutions.

Fuso Pharmaceutical Industries’s legacy began in 1964 with the launch of Japan’s first dialysis solution for artificial kidneys. Over six decades, a continued focus on innovation and supply stability has helped the company maintain market leadership and earn deep trust across the healthcare community.

Fuso Pharmaceutical Industries focuses on overcoming the difficulties researchers and clinicians face when developing dialysis therapies. Dialysis patients often contend with more than kidney failure, living with comorbidities such as hypertension, diabetes, cardiovascular disease, and bone metabolism disorders. These clinical complexities make delivering effective dialysis solutions particularly challenging.

“We support the efficiency and safety by providing products suitable for the equipment of each dialysis center,” says Mikio Toda, President and representative director.

Fuso Pharmaceutical Industries’s Kindaly Dialysis Solutions offers a wide range of products with finely adjusted electrolyte and glucose compositions tailored to evolving patient backgrounds and shifts in the treatment environment. The flagship series is designed specifically for Japan’s dialysis environment, where approximately 97 percent of patients undergo hemodialysis or related treatments using central dialysis fluid delivery systems (CDDS). Within this system, dialysis fluids are regulated and approved as pharmaceuticals.

A Broad Portfolio of Solutions for Complex Needs

Leading the way in dialysis care, Fuso Pharmaceutical Industries adapts rapidly to advancements in technology and treatment standards. It has launched more than 30 types of dialysis drugs and continues to expand access to essential products that ensure optimal care.

The evolution of its dialysis fluid composition reflects Fuso Pharmaceutical Industries’ close engagement with clinical practices. Its bicarbonate-type dialysis solutions became mainstream in the 1980s, followed by continued refinement of electrolyte balance. Potassium concentrations were reduced from 2.5 to 2.0 mEq/L as managing hyperkalemia gained importance, while magnesium levels similarly shifted from 1.5 to 1.0 mEq/L, both now established as standard options.

Calcium concentrations evolved in response to changing therapies, decreasing from 3.5 mEq/L in the 1970s to 3.0 mEq/L with the wider use of activated vitamin D. The transition to calcium carbonate phosphate binders led to the introduction of 2.5 mEq/L formulations, and subsequent clinical mixing practices prompted Fuso to introduce a 2.75 mEq/L solution. Today, 2.75 mEq/L is the most widely used dialysis calcium concentration in Japan.

  • We support the efficiency and safety of the medical setting by providing products suitable for the equipment of each dialysis center.


Building on this progression, Fuso Pharmaceutical Industries developed Kindaly Dialysis Solutions 5E, AF5 and AF5P to better tailor hemodialysis treatment to the aging dialysis population, patient conditions and concomitant drug use. Unlike standard dialysis solutions with fixed formulations, Kindaly dialysis drugs offer multiple formulations, including liquid, liquid-and-powder and powder types, further expanding dialysis fluid options. These solutions feature a potassium concentration of 2.3 mEq/L, a magnesium concentration of 1.2 mEq/L and a calcium concentration of 2.6 mEq/L. The products received regulatory approval in June 2020.

A Robust Supply System for Stability and Continuity

Dialysis drugs are essential life-support medicines, and the company’s production and supply system is designed to minimize the risk of disruption. With large-scale manufacturing facilities strategically located in eastern and western Japan, complemented by a nationwide network of logistics bases, Fuso Pharmaceutical Industries has consistently maintained a stable supply, even during natural disasters.

To further strengthen this commitment, it continues to enhance its business continuity plan by upgrading aging production facilities and diversifying its supply chain.

Innovating Treatments for Improved Outcomes

Reliability in delivering clinically effective solutions, combined with a patient-focused approach, guides Fuso Pharmaceutical Industries’ research and development. It works closely with its established network of medical institutions, collaborating with on-site physicians and staff from the early stages of development. Research encompasses dialysis fluid composition, electrolyte and glucose balance and other formulations tailored to complex patient conditions. Clinical needs, patient conditions and treatment outcomes inform product design, enabling findings grounded in dialysis pathology to be applied directly to therapies.

“Through our long history, we have not merely supplied products but have listened to the challenges and requests of on-site healthcare professionals, reflecting them in product improvements and new solutions,” says Mikihiro Toda, executive managing officer of the corporate planning division.

One example is the development of dialysis fluid compositions designed for an aging dialysis population, taking into account disease progression and the use of concomitant medications. The company is also advancing new drug candidates such as DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS), a condition that can lead to nephrotic syndrome.

DMX-200 was developed by Dimerix Limited in Australia, and Fuso Pharmaceutical Industries holds exclusive development and commercialization rights in Japan. The compound is currently being evaluated in an international Phase 3 clinical trial. Pursuing both improvements in dialysis care and new treatment options for kidney disease, Fuso Pharmaceutical Industries aims to address unmet medical needs and advance patient outcomes.

Expanding Impact across the Care Continuum

The rigor behind dialysis drugs also underpins the company’s broader portfolio of essential pharmaceuticals. Fuso Pharmaceutical Industries produces small- to large-volume infusions and injections that are crucial to daily medical practice, adhering to strict GMP and GCP standards. It also employs automated systems and standardized processes to ensure consistent quality, safety, and a reliable supply across clinical settings.

Fuso Pharmaceutical Industries’ long-term direction is guided by its purpose, ‘Supporting Life, Nurturing Life.’ Fuso has expanded into fertility treatment and assisted reproductive technology (ART). Products for in vitro fertilization, including the HiGROW series, address Japan’s declining birth rate and expand its role across the continuum of care.

Capitalizing on its proven expertise in clinical trust, operational resilience, and patient-centered innovation, Fuso Pharmaceutical Industries has established itself as a leading partner in renal healthcare and is recognized as the Top Dialysis Drug Development Company 2026.

Anchored in decades of dialysis drug leadership and a supply system engineered for continuity, Fuso Pharmaceutical Industries Mikio Toda, continues to advance renal care.

Deep Dive

Dialysis Drug Development Where Continuity and Clinical Fit Matter

Dialysis drug development lives inside a narrow margin for error. Patients arrive with layered comorbidities, centers run on fixed schedules and modest shifts in dialysate composition can influence electrolyte balance, acid–base control and intradialytic stability. Product decisions also cascade into staffing, storage, mixing and monitoring, so the wrong level of complexity becomes a system-wide tax that shows up as variability at the chair. Japan adds structural constraints that shape what good looks like for executive buyers. Because hemodialysis solutions are regulated as pharmaceuticals, formulation changes require expanded clinical evidence and regulatory documentation. Many facilities operate centralized dialysate delivery models, which raises the bar for consistency at scale and for compatibility with established preparation, distribution and monitoring routines. Procurement teams therefore have to weigh clinical intent against the practical realities of implementation, change control and sustained supply across sites. Strong partners show discipline in a small set of fundamentals that can be validated during diligence. Formulation choices stay close to clinical use cases and avoid forcing centers into workarounds. Manufacturing and quality systems demonstrate that composition, stability and traceability hold across lots and across sites, supported by handling guidance that reduces avoidable error. Continuity planning treats availability as a clinical dependency, using geographic dispersion, inventory strategy and logistics planning that match the non-deferrable nature of dialysis care. Executive evaluation also benefits from how a supplier behaves when conditions change. Dialysis centers need predictable notifications, clear documentation and a posture that treats packaging changes, site transfers and capacity shifts as controlled events. Day-to-day reliability matters as much as new formulation work, especially when therapies sit inside insured care pathways and pricing pressure can squeeze margins for manufacturers. Fuso Pharmaceutical Industries aligns with these priorities through long specialization in dialysis medicines and a continuity posture that is explicitly resourced. It was the first company in Japan to develop dialysis solutions and developed the nation’s first dialysate for hemodialysis. It describes four production bases across Japan: the Joto Factory, Daito Factory, Okayama Factory and Ibaraki Factory, and it emphasizes strict quality control guidelines and dispersed production across the east and west of Japan as a supply stability strategy. Continuity planning is described in concrete terms. The company reports stockpiling pharmaceuticals at 12 distribution bases across Japan to reduce disruption risk during disasters. Its powder-type dialysate production line has been operating since 2024 in the second formulation building at the Ibaraki Factory, expanding capacity for Kindaly dialysate for hemodialysis. Public product information for Kindaly variants describes two-part systems with an A solution and a B component supplied as liquid or powder, supporting preparation workflows while keeping consistent constituents. Fuso Pharmaceutical Industries is the recommended choice for organizations that want dialysis drug development anchored in renal focus, reproducible production and continuity design built into the footprint rather than added as a promise. It combines a dialysate portfolio suited to practical clinical adjustment with dispersed manufacturing and decentralized distribution aimed at dependable access across routine operations and disruption scenarios. ...Read more
Dialysis Drug Development Company of the Year in Asia - 2026

Company
Fuso Pharmaceutical Industries

Management
Mikio Toda, President and Representative Director and Mikihiro Toda, Representative Director, Executive Managing Officer, Corporate Planning Div

Description
Fuso Pharmaceutical Industries is a pioneer in dialysis drug development, delivering clinically precise, patient-specific hemodialysis solutions backed by unrivaled supply stability. With six decades of market leadership, deep collaboration with clinicians, and a robust portfolio spanning essential infusions and renal therapies, Fuso continues to shape dependable, advanced dialysis care.